Family Management’s Verona Pharma VRNA Stock Holding History

Family Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,751	Closed	-$544K	–	276
2025 Q2	$544K	Buy	+5,751	New	+$426K	0.08%	123

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Family Management's VRNA Position: Q3 2025 in Review

Family Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 5,751 shares — an estimated $544K sold.

Family Management first reported a position in VRNA in Q2 2025 and held it in 1 quarter. The position peaked at $544K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Family Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Family Management sold 5,751 Verona Pharma shares in Q3 2025, an estimated $544K.
Family Management first reported a position in Verona Pharma in Q2 2025 and held it in 1 quarter.
Family Management's Verona Pharma position peaked at $544K in Q2 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Family Management's 13F filing for Q3 2025, filed 13 Nov 2025.